Abivax S.A. (ABVX)
ABVX Stock Price Chart
Explore Abivax S.A. interactive price chart. Choose custom timeframes to analyze ABVX price movements and trends.
ABVX Company Profile
Discover essential business fundamentals and corporate details for Abivax S.A. (ABVX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Oct 2023
Employees
69.00
Website
https://www.abivax.comCEO
Marc de Garidel
Description
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
ABVX Financial Timeline
Browse a chronological timeline of Abivax S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 14 Sept 2026
EPS estimate is -$0.96, while revenue estimate is $778.45k.
Earnings released on 22 May 2026
EPS came in at -$0.70 surpassing the estimated -$0.94 by +24.84%, while revenue for the quarter reached $1.51m , beating expectations by +277.30%.
Earnings released on 23 Mar 2026
EPS came in at -$1.20 falling short of the estimated -$1.07 by -12.55%, while revenue for the quarter reached $515.06k , missing expectations by -71.43%.
Earnings released on 8 Sept 2025
EPS came in at -$0.86 surpassing the estimated -$0.90 by +4.44%, while revenue for the quarter reached $2.37m , beating expectations by +70.56%.
Earnings released on 24 Mar 2025
EPS came in at -$1.55 falling short of the estimated -$0.68 by -128.04%, while revenue for the quarter reached $7.66m , beating expectations by +146.20%.
Earnings released on 7 Nov 2024
EPS came in at -$0.70 surpassing the estimated -$1.28 by +45.50%, while revenue for the quarter reached $3.65m , beating expectations by +7.05%.
Earnings released on 2 Apr 2024
EPS came in at -$1.94 falling short of the estimated -$0.91 by -112.73%, while revenue for the quarter reached $2.56m , beating expectations by +3.70%.
Earnings released on 30 Jun 2023
EPS came in at -$1.58 , while revenue for the quarter reached $2.45m .
Earnings released on 31 Dec 2022
EPS came in at -$1.95 falling short of the estimated -$1.93 by -0.81%, while revenue for the quarter reached $2.42m .
Earnings released on 30 Jun 2022
EPS came in at -$1.84 , while revenue for the quarter reached $2.33m .
Earnings released on 31 Dec 2021
EPS came in at -$1.68 .
ABVX Stock Performance
Access detailed ABVX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
